pharmaceut rate reiter unit state go sg websit
merck co inc
pharma widow orphan stock
upsid tp
recent academ research put us among top stock
creat sharehold valu us stock market year
uss rank group probabl improv sinc
given well execut immunotherapi io market estim
peak sale potenti howev follow last year share price
out-performance stock longer one top pick although
favourit reliabl compound still expect better execut io
drive high-qual ep growth posit surpris sustain cash return
manag success particularli concern us think
medium-term fundament firmli anchor june us
host first investor day five year import opportun
manag persuad sceptic stori io
 think vaccin franchis underappreci
chang trim ep forecast larg due softer
tail revenu higher non-oper expens howev revis ep estim
nonetheless still ahead consensu continu expect keytruda cancer
immunotherapi surpris upsid
valu stock tp base straight averag ev/ebita multipl
dcf unchang sector multipl expans sinc last updat
off-set ep cut tp impli price-to-earnings premium sg
global pharma coverag univers captur strong visibl compani
medium-term growth prospect upsid risk consensu ep forecast
estim impli estim dividend forecast tsr
could wrong would low-single-digit percentag downsid risk
group ebita estim keytruda captur five fewer point market share
first line nsclc lung cancer similar share loss approv
futur indic would impli mid-single-digit downsid ebita although
strateg highli unlik view transform would probabl drive
nc chang
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor make
invest decis pleas appendix end report analyst certif import
merck co inc
merck co known merck sharp dohm msd outsid us origin establish
us subsidiari german compani merck kgaa merck co
import medium-term growth driver immunotherapi io cancer drug keytruda
enter portfolio via acquisit schere plough uss market-
lead franchis vaccin anim health roger perlmutt phd univers
perceiv play critic role reviv uss prospect sinc rejoin
head although doesnt mandatori retir age dr
perlmutt
product relev invest debat usdm
acquisit schere plough
like mani competitor suffer
deflat us
global allianc astrazeneca
book product sale
vaccin
vaccin industri oligopoli
invest debat
enjoy high barrier
reason
reason
market leader immunotherapi potenti market
medium-term growth highli depend keytruda
immunotherapi drive above-averag sale growth posit surpris
unclear succeed ceo head
attract valuat cash return sharehold
capit alloc ownership anim health
merck co inc
get fundament
us compani creat wealth
note wealth creation total stock gain includ dividend excess one-month treasuri bill return compani list follow guidelin
center research secur price compani new iter mark asterisk compani longer trade mark
dagger
new york time prof hendrik bessembind carey school busi arizona state univers
accord academ research merck co one us compani creat
sharehold valu chart doubt whether compani
drop list sinc execut well secur leadership
immunotherapi market forecast above-averag sale ep growth
reason chart
merck co inc
us non-gaap ep chang sg estim comparison consensu /share
trim ep forecast softer tail revenu non-oper item
howev still expect upsid surpris larg expect uss cancer
franchis continu surpris upsid tabl
although merck co offer solid ep growth prospect believ also attract stori
incom investor expect gener annual post-tax free cash flow well
around return sharehold via dividend buyback chart
left also expect bolster organ extern collabor
manag openli acknowledg much best scienc take place outsid
lab howev think far like compani continu make nich bolt-on
acquisit like recent one eisai lenvima rather transform deal
merck co inc
us forward price-to-earnings rel
note sector compos azn astrazeneca bayer
stock rerat end thank eas concern
industry-wid patent cliff chart left uss roll forward price-to-earnings sinc
volatil due uncertainti whether would domin immunotherapi market
investor feedback also indic price-to-earnings somewhat suppress percept keytruda
compani growth driver absolut earn declin next decad
forecast slightli neg ep growth due januvia diabet patent expiri
chart left equat absolut ebit declin year howev
view manag could probabl mitig via new restructur programm
meantim pipelin doesnt surpris upsid see chart bottom right
still assum wacc perpetu growth rate
part
consid success merck co enjoy immunotherapi past one
two year believ invest debat shift away phase readout
financi execut therefor believ import mileston next
month quarterli result see next tabl
merck co inc
tabl model impact central scenario posit
neg take relev product current portfolio late-stag
pipelin help us calibr magnitud risk compani face go
forward use ebit analysi given long product cycl
pharmaceut industri merck co forecast upsid risk ebit
estim downsid vs
sale profil bull vs bear usdm
sale varianc sourc upsid downsid
ebit varianc sourc upsid downsid
merck co inc
driver drag sale
revenuedeclin revenu sale
merck co inc
merck co inc
except ep dp
product sold
net earn sharehold
equival
total liabil equiti
chang work capit
flow oper activ
purchas secur net
flow invest activ
net chang debt
proce issue/buyback share
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
end year
flow invest activ
flow financ activ
net chang cash result cf
intang
merck co inc
merck co inc
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
merck co inc
report complet cet
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report justin smith
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
merck co inc us buy
histor price merck co inc mrk
valuat methodolog merck co inc
tp straight averag sotp base peer group averag ev/ebita multipl dcf wacc termin
growth target price-to-earnings impli multipl expans premium global pharma univers captur
upsid risk consensu ep forecast
would low singl digit percentag downsid group ebita estim keytruda captur five fewer share point either
nsclc lung cancer similar share loss approv futur indic would impli mid-singl digit downsid
merck co inc
equiti rate dispers relationship
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin use
creat financi product includ indic inform provid basi user assum entir risk
use made inform affili third parti involv relat comput compil inform
herebi expressli disclaim warranti origin accuraci complet merchant fit particular purpos
respect inform without limit forego event shall affili third parti involv
relat comput compil inform liabil damag kind morgan stanley capit
index servic mark affili similar languag may provid approv
advanc
